Kodiak Sciences Inc. filings document a Nasdaq-listed biotechnology issuer developing retinal medicines through its ABC Platform and related biologic programs. Recent Form 8-K reports record financial results, business highlights, clinical disclosures for Zenkuda, KSI-501 and KSI-101, and capital-structure events involving common stock.
Proxy materials describe annual meeting matters, shareholder voting procedures, executive compensation and equity award disclosures. Offering-related 8-K disclosures record the completed underwritten public offering of common stock, underwriting agreement terms, registered security details and related exhibits.
Point72 Asset Management, Point72 Capital Advisors, and Steven A. Cohen reported beneficial ownership of Kodiak Sciences Inc. common stock amounting to 2,166,929 shares, or 3.5% of the company’s outstanding shares as of December 31, 2025.
The filing states that Point72 Asset Management has investment and voting power over shares held by an investment fund it manages, with Point72 Capital Advisors as its general partner and Mr. Cohen controlling both entities. The ownership percentage is based on 61,048,428 Kodiak shares outstanding, reflecting recent offerings and previously reported outstanding shares. The reporting persons note they are not holding the securities for the purpose of changing or influencing control of Kodiak Sciences.
Kodak Sciences Inc. large shareholder D. Victor Perlroth, M.D. filed an amended Schedule 13G/A reporting his beneficial ownership of the company’s common stock as of December 31, 2025. He reports beneficial ownership of 6,504,427 shares, representing 9.9% of Kodiak’s outstanding common stock.
The filing explains this stake includes shares held directly, options exercisable within 60 days, shares held by a family foundation, and shares subject to a voting agreement and proxy where he has voting but not investment power. The percentage is based on 61,758,454 shares outstanding as of December 31, 2025.
Kodiak Sciences Inc. completed a public underwritten offering of 8,000,000 shares of its common stock, including 1,043,478 shares issued when the underwriters fully exercised their 30-day option. The shares were sold to investors at $23.00 per share, while the underwriters purchased them from the company at $21.62 per share under an underwriting agreement with J.P. Morgan Securities, Jefferies, Evercore Group and UBS Securities. The transaction generated approximately $184 million in gross proceeds for Kodiak Sciences before underwriting discounts, commissions and other offering expenses. The offering was conducted under an effective Form S-3 shelf registration statement and related prospectus supplements.
Kodiak Sciences Inc. is conducting a primary offering of 6,956,522 shares of common stock at $23.00 per share, raising estimated net proceeds of about $149.9 million after underwriting discounts and expenses. Underwriters also have a 30‑day option to buy up to 1,043,478 additional shares. Kodiak expects 59,955,083 shares outstanding after the offering, or 60,998,561 shares if the option is fully exercised, compared with 52,998,561 shares as of September 30, 2025.
The company plans to use the cash, together with existing funds, for working capital and general corporate purposes as it advances three late‑stage retinal drug candidates (KSI‑101, KSI‑501 and tarcocimab) across multiple Phase 3 trials, with several topline readouts expected between 2026 and 2027. At the $23.00 offering price, new investors face immediate net tangible book value dilution of $20.10 per share, as adjusted book value would rise from $0.45 to $2.90 per share. Entities affiliated with Baker Bros. Advisors and director Dr. Felix J. Baker have indicated interest in purchasing up to one‑third of the offered shares, though this indication is not binding.
Kodiak Sciences Inc. is offering 6,000,000 shares of its common stock in an underwritten public transaction, and has granted the underwriters a 30-day option to purchase up to 900,000 additional shares. Based on 52,998,561 shares outstanding as of September 30, 2025, Kodiak expects to have 58,998,561 shares outstanding after the offering, or 59,898,561 shares if the option is exercised in full.
The company plans to use the net proceeds, together with current cash and cash equivalents, for working capital and general corporate purposes. Entities affiliated with Baker Bros. Advisors LP and director Dr. Felix J. Baker have indicated interest in purchasing up to an aggregate of one-third of the shares at the public offering price, although these indications are not binding. Kodiak is a precommercial retina-focused biotechnology company developing late-stage investigational therapies KSI-101, KSI-501 and tarcocimab across multiple Phase 3 trials, with key topline data expected between 2026 and 2027.
Investors in this offering face a high degree of risk, including immediate dilution in net tangible book value, the possibility of future equity offerings, and the company’s stated intention not to pay cash dividends, meaning potential returns would rely on stock price appreciation.
Kodiak Sciences (KOD) reported a wider quarterly loss and flagged going concern risk. For the quarter ended September 30, 2025, net loss was $61.5 million with basic and diluted loss per share of $1.16. Year-to-date net loss reached $173.2 million as research and development spending rose to support multiple late‑stage programs.
Cash and cash equivalents were $72.0 million as of September 30, 2025, down from $168.1 million at year‑end, with $96.6 million used in operating activities over nine months. Management states there is substantial doubt about the company’s ability to continue as a going concern without additional financing. Stockholders’ equity was $23.7 million; a $100.0 million liability related to sale of future royalties remains outstanding.
Pipeline progressed with Phase 3 studies: GLOW2 (DR) and DAYBREAK (wet AMD) have completed enrollment, with topline readouts targeted for 1Q 2026 and 3Q 2026, respectively. KSI‑101 Phase 3 (MESI) trials PEAK and PINNACLE are enrolling, with topline data targeted for 4Q 2026 and 1Q 2027. As of November 6, 2025, common shares outstanding were 53,048,428.
Kodiak Sciences Inc. furnished a Form 8-K under Item 2.02 announcing it issued a press release with financial results for the quarter ended September 30, 2025 and business highlights.
The press release is attached as Exhibit 99.1. The company states this information is being furnished and shall not be deemed “filed” under Section 18 of the Exchange Act. Kodiak’s common stock trades on Nasdaq under the symbol KOD.
Kodiak Sciences Inc. Schedule 13G filed by Point72-related filers reports collective beneficial ownership of 2,908,836 shares of Kodiak Sciences common stock, representing 5.5% of the class as of the close of business on August 18, 2025. The filing attributes shared voting and shared dispositive power of all reported shares to Point72 Asset Management, Point72 Capital Advisors, Inc., and Steven A. Cohen, with no sole voting or dispositive power reported. Point72 Associates holds the shares and Point72 Asset Management acts as investment manager; Point72 Capital Advisors is the general partner and Mr. Cohen controls the entities. The filers state the shares were not acquired to change or influence control of the issuer. A Joint Filing Agreement is filed as Exhibit 99.1.
Kodiak Sciences Inc. (KOD) reported continued clinical progress alongside significant cash burn and liquidity concerns. For the six months ended June 30, 2025 the company recorded a net loss of $111.8 million and used $63.8 million of cash in operations. The company reported $104.2 million of cash and cash equivalents as of June 30, 2025 (and $110.349 million including restricted cash), an accumulated deficit of $1,440,512 (amounts presented in thousands) and a $100,000 liability related to the sale of future royalties. Management states there is substantial doubt about the company’s ability to continue as a going concern and plans to seek additional financing.
Operationally, Kodiak is advancing multiple late-stage programs. GLOW2 enrollment is complete (more than 250 patients) with topline data expected 1Q 2026; DAYBREAK (tarcocimab and KSI-501) remains actively enrolling with topline data expected 3Q 2026 and the company intends to seek a single BLA in 2026 following these results. KSI-101 completed Phase 1b APEX with selected doses moving into Phase 3 PEAK and PINNACLE, which are actively enrolling. The company recognized a $1.9 million non-cash lease impairment tied to a sublease and recorded sublease income in 2025. Research and development expense rose materially to $86.4 million for the six months ended June 30, 2025, reflecting expanded pivotal trials and manufacturing work.
Kodiak Sciences Inc. disclosed in a Form 8-K dated August 13, 2025 that it published a press release reporting the company’s financial results for the quarter ended June 30, 2025 and related business highlights; that press release is attached as Exhibit 99.1 to this report.
The filing states the press release and information contained or incorporated herein shall not be deemed "filed" for purposes of Section 18 of the Exchange Act and will not be incorporated by reference into other filings except by specific reference. The 8-K lists an Inline XBRL cover page as Exhibit 104 and is signed by Victor Perlroth, M.D., Chief Executive Officer. The company’s common stock trades under the ticker KOD on The Nasdaq Stock Market.